FDA Rejects SGLT Drug Zynquista for T1D Use

Lexicon Pharmaceuticals developed Oral Treatment with Sanofi

The FDA declined to approve Zynquista a drug developed by Sanofi SA and Lexicon Pharmaceuticals intended for use with insulin in patients with Type 1 Diabetes.  The generic name of the drug is sotagliflozin.

The decision comes about two months after an FDA advisory panel divided over whether the once-daily oral drug should be approved as an add-on to insulin therapy.

Sotagliflozin, works by inhibiting the proteins SGLT1 and SGLT2 to help regulate blood glucose levels by removing excess blood sugar through the urine and reduce the risk of weight gain.

Martin is the Founder of SelfRx Media and editor-in-chief of Insulin Nation. He's a passionate about sharing knowledge with those affected by Diabetes.

Related Articles

Back to top button